{"preliminary_commentary":{"by_channel":{"x_thread":7,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02838420\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["alectinib"]],"indication":"treatment-naive advanced ALK-positive non-small cell lung cancer","name":"ALESIA","nct_id":"NCT02838420","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=alesia-nct02838420. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death.","label":"Alectinib","type":"EXPERIMENTAL"},{"description":"Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death.","label":"Crizotinib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-05-11","type":"ACTUAL"},"conditions":["Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer"],"enrollment":{"count":187,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Alectinib","otherNames":["RO5424802"],"type":"DRUG"},{"name":"Crizotinib","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-24","lead_sponsor":"Hoffmann-La Roche","official_title":"Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2018-05-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1","timeFrame":"From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months)"}],"references":[{"citation":"Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10.","pmid":"30981696","type":"DERIVED"}],"start_date":{"date":"2016-08-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT02838420"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/alesia-nct02838420"}